Itaconate as a key regulator of respiratory disease.

Publication date: Nov 29, 2023

Macrophage activation results in the accumulation of endogenous metabolites capable of adopting immunomodulatory roles; one such bioactive metabolite is itaconate. After macrophage stimulation, the TCA-cycle intermediate cis-aconitate is converted to itaconate (by aconitate decarboxylase-1, ACOD1) in the mitochondrial matrix. Recent studies have highlighted the potential of targeting itaconate as a therapeutic strategy for lung diseases such as asthma, idiopathic pulmonary fibrosis (IPF), and respiratory infections. This review aims to bring together evidence which highlights a role for itaconate in chronic lung diseases (such as asthma and pulmonary fibrosis) and respiratory infections (such as SARS-CoV-2, influenza and Mycobacterium tuberculosis infection). A better understanding of the role of itaconate in lung disease could pave the way for novel therapeutic interventions and improve patient outcomes in respiratory disorders.

Concepts Keywords
Fibrosis itaconate
Immunomodulatory macrophages
Mitochondrial Respiratory disease
Pulmonary
Tuberculosis

Semantics

Type Source Name
disease MESH lung diseases
disease MESH asthma
pathway KEGG Asthma
disease MESH idiopathic pulmonary fibrosis
disease MESH respiratory infections
disease MESH pulmonary fibrosis
disease MESH influenza
disease MESH Mycobacterium tuberculosis infection
drug DRUGBANK Tropicamide

Original Article

(Visited 1 times, 1 visits today)